Medical Genetics & Endocrinology & Urology & Family Medicine
Klinefelter Syndrome (47,XXY)
Klinefelter syndrome (KS) is the most common sex chromosome aneuploidy in males, with a prevalence of approximately 1 in 500 to 1 in 700 male births—meaning about 150,000 men are affected in Canada. It is caused in 80–90% of cases by a 47,XXY karyotype (meiotic nondisjunction during parental gametogenesis, of maternal origin in 55–60% and paternal in 40–45% of cases) and in 10–20% of cases by variant forms (mosaics 46,XY/47,XXY + 48,XXXY + 48,XXYY + 49,XXXXY + extra X chromosomes). Despite its prevalence, Klinefelter syndrome remains largely underdiagnosed—it is estimated that only 25–30% of affected men receive a diagnosis during their lifetime, and often as adults during infertility evaluation. The clinical spectrum is highly variable, ranging from nearly asymptomatic men to forms with marked delayed puberty, severe hypogonadism, gynecomastia, learning difficulties, and infertility. The underlying mechanism is progressive fibrosis of the testicular seminiferous tubules beginning at puberty—leading in nearly all cases to azoospermia—as well as hypergonadotropic hypogonadism (elevated FSH and LH + low testosterone) due to Leydig cell failure. Testosterone replacement therapy improves the symptoms of hypogonadism. The TESE (Testicular Sperm Extraction) combined with ICSI (Intracytoplasmic Sperm Injection) now allows 50–70% of men with Klinefelter syndrome to recover viable testicular sperm for assisted reproductive technology.
Genetics, pathophysiology, and clinical manifestations
- Genetics and pathophysiological mechanisms of Klinefelter syndrome: Genetic basis: 47,XXY karyotype: the extra X chromosome results from meiotic nondisjunction during gamete formation → origins: maternal (maternal meiosis I or II — 55–60 %) + paternal (paternal meiosis II — 40–45 %) → the extra X chromosome is inactivated (Lyonization) in most somatic cells → but: inactivation is incomplete → certain genes in the pseudoautosomal region (PAR) and other loci escape inactivation → increased gene dosage → contribution to SK-specific phenotypes → variant forms: 46,XY/47,XXY (10–15 %): milder phenotype → less hypogonadism → possibility of sperm in the ejaculate → 48,XXXY + 48,XXYY + 49,XXXXY: severe forms → intellectual disability + associated malformations → each additional X chromosome exacerbates the phenotype; pathophysiological mechanisms: progressive testicular fibrosis: expression of genes on the additional X chromosome (uninactivated) in Sertoli cells → accelerated apoptosis of germ cells → fibrosis of the seminiferous tubules → at puberty → rapid progression of fibrosis → most seminiferous tubules are hyalinized by age 20–25 years of age → a few foci of residual spermatogenesis persist in some tubules → basis for TESE + Leydig cell failure: reduced Leydig cell mass + impaired function → low testosterone → elevated LH (without sufficient negative feedback) + elevated FSH (absence of inhibin B and functional Sertoli cells) → hypergonadotropic hypogonadism → effects of testosterone deficiency: delayed or absent virilization at puberty + reduced muscle mass + osteoporosis + abdominal obesity + metabolic disorders + erectile dysfunction + mood disorders + depression + fatigue + gynecomastia: accumulation of adipose tissue in the breasts + altered testosterone/estradiol ratio → peripheral androgens are aromatized into estrogens → gynecomastia → increased risk of male breast cancer (×50 vs. the general male population); neurodevelopmental effects of the extra X chromosome: X-chromosome genes involved in brain development → delayed speech + reading difficulties + learning difficulties + attention disorders + ADHD + autism spectrum traits in some cases → but: the majority of men with SK have normal intelligence → forms with multiple extra X chromosomes (48,XXXY + 49,XXXXY) are more likely to present with intellectual disability
- Clinical manifestations by life stage: Prenatal period: often diagnosed during prenatal testing (amniocentesis + chorionic villus sampling) → for other indications (maternal age + ultrasound abnormality) + incidental prenatal diagnosis → genetic counseling + management → early childhood and childhood (<12 years): language delay + learning difficulties + delayed walking + small testicles (often unnoticed at this age) + some boys are diagnosed as hyperactive or exhibit social difficulties → the diagnosis is rarely made in pediatrics unless complications arise + puberty and adolescence: onset of puberty sometimes normal → but: incomplete progression + small testicles (testicular volume <6–8 mL — N: 15–25 mL) → key finding on examination → testicles remain small and firm (fibrosis) + gynecomastia (50–60% of SK adolescents) + reduced facial, axillary, and pubic hair + tall stature (long torso + long legs + abnormally high wingspan-to-height ratio) + incomplete puberty: no normal muscle development + voice does not fully break + apparent pubertal delay + adulthood (most common diagnosis): infertility (most common reason for consultation — azoospermia) + hypogonadism: chronic fatigue + decreased libido + erectile dysfunction + osteoporosis + persistent gynecomastia + abdominal obesity + metabolic syndrome + T2D + increased cardiovascular risk + increased risk of venous thromboembolism (VTE) (probable link to testosterone deficiency + associated risk factors) + increased risk of systemic lupus erythematosus (SLE) (the extra X chromosome expressing autoimmune genes) + male breast cancer (× 50 vs. general population) → breast monitoring recommended
Diagnosis, treatment, and fertility
| Aspect / Domain | Data, diagnostic criteria, and modalities | Key studies and recommendations |
|---|---|---|
| Diagnostic — karyotype, hormonal panel, and clinical presentation Karyotype 47,XXY — elevated FSH — elevated LH — low testosterone — inhibin B — AMH — small testes — azoospermia — semen analysis — DXA osteoporosis — metabolic panel — metabolic syndrome |
Diagnosis of Klinefelter syndrome: karyotyping of blood lymphocytes: gold standard method → performed on peripheral blood → results in 2–3 weeks → 47,XXY confirmed → if mosaic is suspected → karyotyping of at least 50 cells → or FISH (Fluorescence In Situ Hybridization) → results in 48–72 hours → FISH on buccal smear: rapid but less accurate than karyotyping → for screening → not for confirmation → hormonal evaluation starting at puberty: FSH: elevated (>15–20 IU/L) → sign of Sertoli cell failure → LH: elevated (>10–12 IU/L) → hypergonadotropic hypogonadism + total testosterone: low (often <10–12 nmol/L — N: 12–35 nmol/L) → may be normal at the onset of puberty + inhibin B: severely reduced or undetectable → marker of Sertoli cell destruction → AMH (Anti-Müllerian Hormone): also low post-puberty → marker of Sertoli cell function + SHBG (Sex Hormone Binding Globulin): often elevated → reduces bioavailable free testosterone + estradiol: altered testosterone/estradiol ratio → gynecomastia → semen analysis (adult): azoospermia in 90–95% of cases → severe oligospermia in 5–10% (especially mosaic forms 46,XY/47,XXY) → physical examination: testicular volume: small, firm testes (<6–8 mL — N: 15–25 mL) → most consistent physical sign → Prader orchidometry + height: often above average (long torso + long legs) → gynecomastia (50–60% of cases) + reduced body hair + poor muscle development + assessment of complications to be performed in all adult men diagnosed with SK: bone densitometry (DXA): osteopenia + osteoporosis common → glucose profile (HbA1c + fasting blood glucose): T2D + metabolic syndrome + lipid panel + BP + waist circumference → cardiovascular risk → thyroid panel (TSH) + psycho-cognitive assessment (if learning difficulties) + breast ultrasound if gynecomastia + autoimmune workup (SLE + thyroiditis in SK) + genetic counseling + fertility counseling | Lanfranco 2004 — Lancet: Complete review of Klinefelter syndrome → epidemiology + phenotype + treatment → international reference + Bonomi 2017 — Human Reproduction Update: Review of pathophysiology + manifestations + diagnosis + Groth 2012 — European Journal of Human Genetics: Prevalence of KS + underdiagnosis + mass cohort + Aksglaede 2013 — American Journal of Medical Genetics: Klinefelter → long-term complications + follow-up + Zitzmann 2010 — Journal of Clinical Endocrinology and Metabolism: Metabolic manifestations + cardiovascular + KS + testosterone treatment + Endocrine Society Guidelines 2018 (Bhatt — Journal of Clinical Endocrinology and Metabolism): Male hypogonadism + treatment → CSEM (Canadian Society of Endocrinology and Metabolism) + CAS (Canadian Andrology Society): Canadian recommendations + INESSS Quebec: Hormonal assessment for KS + testosterone reimbursed for confirmed male hypogonadism |
| Testosterone therapy and multidisciplinary care Testosterone replacement — Androgel — Andriol — Depo-Testosterone — testosterone undecanoate — pubertal induction — gynecomastia — osteoporosis — DXA — cardiovascular assessment — testosterone monitoring — hematocrit — PSA — breast cancer |
Testosterone replacement therapy — a cornerstone of hypogonadism treatment in SK: goals: virilization + maintenance of libido + erections + muscle mass + bone density + mood + energy + overall well-being → initiation: at puberty (if hypogonadism is confirmed: testosterone <10 nmol/L + elevated FSH + LH) + in adults upon diagnosis if testosterone is low and symptoms of hypogonadism are present → formulations available in Canada (RAMQ): testosterone gel (Androgel 1 % + Testim): 25–75 mg/day applied to the shoulders and abdomen → advantages: stable + easy to adjust → disadvantage: skin transfer if contact occurs → long-acting injectable testosterone undecanoate (Nebido 1,000 mg/4 mL IM): every 10–14 weeks → advantage: adherence + quarterly administration → testosterone crystals (Depo-Testosterone cypionate 100–200 mg IM every 2 weeks → or Delatestryl enanthate) → oral testosterone undecanoate (Andriol): less commonly used (variable absorption) → treatment target: testosterone in the upper-middle range of normal (15–25 nmol/L) → measure halfway between injections (or at any time with the gel) → monitoring during testosterone therapy: hematocrit: risk of polycythemia (testosterone stimulates erythropoiesis) → target hematocrit <54 % → if >54 % → reduce dose or interval → CBC every 3–6 months in the first year + annually → PSA: measure before initiation + at 3–6 months + annually if >45 years old → if PSA rises rapidly or reaches 4 ng/mL → urological evaluation → testosterone contraindicated if: prostate cancer + male breast cancer + hematocrit >54 % + severe untreated sleep apnea + decompensated heart failure → lipid and glucose monitoring annually + DXA (bone densitometry): at baseline + every 2 years → if osteoporosis: bisphosphonate + calcium + vitamin D → gynecomastia in the SK: treatment if causing cosmetic distress or pain → testosterone may improve gynecomastia if started early (before fibrosis) → if fibrosis is already established → surgery (subcutaneous mastectomy) → management of male breast cancer × 50 vs. general population → recommendation: monthly self-exam + mammogram if lump + asymmetric gynecomastia → psychosocial support: supportive therapy + peer groups (e.g., Association Klinefelter Québec) + academic and career support if cognitive difficulties + ADHD treatment if associated | Zitzmann 2010 — JCEM: metabolic manifestations + testosterone → improved body composition + metabolism Snyder 2016 — NEJM (Testosterone Trials; TT trials, n=788 hypogonadal men): testosterone + hypogonadism → improved sexual function + bone density + muscle strength Bhatt 2018 — JCEM (Endocrine Society Guidelines): male hypogonadism → testosterone treatment → indications + monitoring → formulations + targets Lanfranco 2004 — Lancet: hypogonadism → treatment + prognosis Pacenza 2012 — Journal of Andrology: hypogonadism + testosterone + well-being Bonomi 2017 — Human Reproduction Update: management of hypogonadism Groth 2012 — EJHG: underdiagnosis of hypogonadism + screening → CSEM (Canadian Society of Endocrinology and Metabolism) SCFA (Canadian recommendations): testosterone + hypogonadism + RAMQ Quebec: testosterone reimbursed if confirmed hypogonadism (testosterone <8 nmol/L + symptoms) INESSS (Quebec's National Institute of Excellence in Health and Social Services): male hormone replacement protocols |
| Fertility — TESE-ICSI and Genetic Counseling TESE testicular sperm extraction — ICSI intracytoplasmic sperm injection — sperm retrieval rate — micro-TESE — spermatogenesis foci — PGT-A — genetic counseling — offspring karyotype — cryopreservation — IVF — low predictive value of inhibin B |
Fertility in Klinefelter syndrome — TESE + ICSI: non-obstructive azoospermia in 90–95% of men with Klinefelter syndrome → a few foci of residual spermatogenesis persist in some seminiferous tubules (despite generalized fibrosis) → these foci of spermatogenesis can be surgically harvested → TESE (Testicular Sperm Extraction): biopsy or surgical extraction of testicular sperm → conventional TESE → or micro-TESE (microsurgical TESE): surgical magnifying glass × 20–25 → identifies the more dilated testicular areas (more likely to contain sperm) → sperm recovery rate with micro-TESE in the SK: 50–70% (Ramasamy 2009 — Journal of Andrology + Palermo 2012 — Fertility and Sterility) → live birth rate per IVF-ICSI cycle after successful micro-TESE: 40–50 % if female partner is ≤35 years old → factors associated with better sperm retrieval: younger age (<35 years) → before complete fibrosis → low FSH (relative — indicating less tubular destruction) → larger testicular volume (relative — more residual tissue) → BUT: no serum markers (inhibin B + FSH + LH + testosterone) can reliably predict TESE success → TESE should not be refused solely based on unfavorable lab results + testosterone should NOT be administered in preparation for TESE (testosterone inhibits residual spermatogenesis by suppressing FSH and LH → worsens azoospermia) → if desiring fatherhood → discontinue testosterone + wait 6–12 months before TESE → or use hCG + recombinant FSH to stimulate spermatogenesis before TESE → optimal timing for TESE: adolescence or young adulthood (before fibrosis worsens) → cryopreservation of sperm during adolescence increasingly recommended (if TESE is successful) → Tournaye 2012 — Fertility and Sterility: TESE in adolescents with SK + cryopreservation → Lanfranco 2004 — Lancet: TESE in SK + success rates; genetic counseling and PGD: mandatory genetic counseling before IVF-ICSI: risk of transmitting an abnormal karyotype to offspring: SK is generally sporadic (non-hereditary) → but: slightly increased risk of aneuploidy in the sperm of men with SK (even those recovered by TESE): 6–8% of SK sperm are aneuploid (XX + XY + XXY + etc.) vs. 1–2 in 1,000 in the general population → slightly increased risk of offspring with chromosomal abnormalities (Klinefelter + Turner + Down) compared to the general population → but: absolute risk remains low → PGD-A (preimplantation genetic diagnosis for aneuploidies): biopsy of blastocyst trophoblast cells + NGS → selection of euploid embryos → reduces the risk of pregnancy with an abnormal karyotype → offered in certain specialized centers in Quebec + recommendation to discuss PGD with SK couples before IVF-ICSI + Röpke 2021 — Human Reproduction: sperm aneuploidy in SK + risk to offspring | Ramasamy 2009 — Journal of Andrology: micro-TESE + SK → recovery rate 50–70% % → reference + Palermo 2012 — Fertility and Sterility: ICSI + SK + live birth rate → reproductive outcomes + Lanfranco 2004 — Lancet: SK → fertility + TESE + prognosis + Tournaye 2012 — Fertility and Sterility: adolescent TESE + SK + cryopreservation → early recommendation + Röpke 2021 — Human Reproduction: sperm aneuploidy + SK + offspring risk + genetic counseling + SCFA (Canadian Society for Fertility and Andrology): TESE-ICSI in SK → protocols + Canadian recommendations + ESHRE 2023: ART in non-obstructive azoospermia → TESE + SK + Schiff 2005 — Journal of Urology: micro-TESE SK + results + King 2015 — Human Reproduction Update: review of reproductive outcomes in SK → TESE + ICSI + RAMQ Quebec: IVF-ICSI coverage for non-obstructive azoospermia + INESSS: TESE + IVF-ICSI protocols for severe male infertility |
ℹ️
Testosterone should NOT be prescribed to a Klinefelter man who desires paternity — it suppresses residual spermatogenesis by inhibiting FSH and LH: If a couple is planning to have a child, TESE (ideally micro-TESE) should be performed either before or instead of testosterone therapy, or after a 6- to 12-month break. Micro-TESE allows for sperm retrieval in 50 to 70% of men with Klinefelter syndrome, and live birth rates via IVF-ICSI are 40 to 50% if the partner is under 35 years of age. No biological marker can reliably predict the success of TESE—therefore, it should not be refused solely on the basis of undetectable inhibin B or very high FSH levels.
Situations requiring urgent or priority specialist consultation
Adolescent with small testicles (volume <6 mL) + gynecomastia + delayed virilization + very high FSH and LH + low testosterone for pubertal age → probable Klinefelter syndrome → urgent karyotype → if confirmed: testosterone treatment to be initiated as soon as possible (improves virilization + reduces gynecomastia if started early) + genetic counseling + multidisciplinary management (pediatric endocrinology + urology + psychology).
Adult male with azoospermia + very high FSH (>20 IU/L) + small testicles + karyotype 47,XXY not yet performed Klinefelter until proven otherwise → urgent karyotype → if confirmed AND desire for paternity → DO NOT initiate testosterone → reproductive medicine + andrology consultation → micro-TESE + IVF-ICSI + genetic counseling + PGD-A discussed → RAMQ: IVF-ICSI covered if non-obstructive azoospermia.
Male with Klinefelter syndrome who has been on testosterone therapy for several years, with a hematocrit >54%, %, headaches, and hyperviscosity → Polycythemia on testosterone → Reduce or suspend testosterone → Phlebotomy if severe symptoms → Reduce dose upon resumption → Switch to gel (more stable levels) + monthly CBC monitoring until normalization.
Klinefelter man with unilateral breast nodule + asymmetric gynecomastia + hard mass → Male breast cancer to rule out (50x risk vs general population) → mammography + biopsy + urgent oncological consultation → Male breast cancer in the UK is often ER+ → hormone therapy (tamoxifen) + surgery + if benign gynecomastia without nodule → subcutaneous mastectomy if significant discomfort.
Consult at Clinique Omicron
Clinique Omicron's physicians suspect and diagnose Klinefelter syndrome in men presenting with infertility, hypogonadism, and small testes. They prescribe karyotyping and a complete hormonal assessment, initiate and monitor testosterone replacement therapy (including monitoring hematocrit, PSA, and bone densitometry), refer to an endocrinologist for complex hypogonadism management, and to a reproductive medicine center for TESE-ICSI if fatherhood is desired. Consultations are available at several service points in Quebec and via telemedicine. To book an appointment, visit cliniqueomicron.ca.
The content of this page is for informational purposes only and does not substitute for the advice of a physician, endocrinologist, or geneticist. The management of Klinefelter syndrome is multidisciplinary and should be individualized according to the patient's age, symptoms, and parental project.
Omicron Clinic
Need to consult a doctor?
Treatment within 24-48 hours. In-clinic or telemedicine, anywhere in Quebec.
Insurance receipts. 7j/7. No family doctor required.